ATRX and glioblastoma: ATRX loss-of-function in glioblastoma results in a genetically unstable tumor that when left untreated is more aggressive than those with ATRX function, but the former is more responsive to double-stranded DNA-damaging agents (doxorubicin, irinotecan, and topotecan), resulting in improved overall survival.25